The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
Open accessAbstract
BACKGROUND: Germline genetic testing with hereditary cancer gene panels can identify women at increased risk of breast cancer. However, those at increased risk of triple-negative (estrogen receptor-negative, progesterone receptor-negative, human epidermal growth factor receptor-negative) breast cancer (TNBC) cannot be identified because predisposition genes for TNBC, other than BRCA1, have not been established. The aim of this study was to define the cancer panel genes associated with increased risk of TNBC. METHODS: Multigene panel testing for 21 genes in 8753 TNBC patients was performed by a clinical testing laboratory, and testing for 17 genes in 2148 patients was conducted by a Triple Negative Breast Cancer Consortium (TNBCC) of research studies. Associations between deleterious mutations in cancer predisposition genes and TNBC were evaluated using results from TNBC patients and reference controls. RESULTS: Germline pathogenic variants in BARD1, BRCA1, BRCA2, PALB2, and RAD51D were associated with high risk (odds ratio > 5.0) of TNBC and greater than 20% lifetime risk for overall breast cancer among Caucasians. Pathogenic variants in BRIP1, RAD51C, and TP53 were associated with moderate risk (odds ratio > 2) of TNBC. Similar trends were observed for the African American population. Pathogenic variants in these TNBC genes were detected in 12.0% (3.7% non-BRCA1/2) of all participants. CONCLUSIONS: Multigene hereditary cancer panel testing can identify women with elevated risk of TNBC due to mutations in BARD1, BRCA1, BRCA2, PALB2, and RAD51D. These women can potentially benefit from improved screening, risk management, and cancer prevention strategies. Patients with mutations may also benefit from specific targeted therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
A Direct Approach to False Discovery Rates
Storey, J. D. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00346 · Cited by 5,603
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Self-citationGene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., Devilee, P., Meindl, A., Couch, F. J., Southey, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1501341 · Cited by 920
Self-citationBreast-Cancer Risk in Families with Mutations in PALB2
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 851
Self-citationInherited Mutations in Women With Ovarian Carcinoma
Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Yi, Q., Burger, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5495 · Cited by 769
Walsh, R., Thomson, K. L., Ware, J. S., Funke, B. H., Woodley, J., McGuire, K. J., Mazzarotto, F., Blair, E., Seller, A., Taylor, J. C., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.90 · Cited by 734
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 672
Self-citation
Cited by
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 529
RetractedKurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., Miller, D., Penberthy, L. S., & Katz, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01854 · Cited by 387
Epidemiology of Triple-Negative Breast Cancer: A Review
Howard, F. M., & Olopade, O. I. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000500 · Cited by 338
Metadata
- Authors
- Shimelis, H., LaDuca, H., Hu, C., Hart, S. N., Na, J., Thomas, A., Akinhanmi, M., Moore, R. M., Brauch, H., Cox, A., Eccles, D. M., Ewart-Toland, A., Fasching, P. A., Fostira, F., Garber, J., Godwin, A. K., Konstantopoulou, I., Nevanlinna, H., Sharma, P., Yannoukakos, D., Yao, S., Feng, B.-J., Tippin Davis, B., Lilyquist, J., Pesaran, T., Goldgar, D. E., Polley, E. C., Dolinsky, J. S., & Couch, F. J.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-08-01
- Volume
- 110
- Issue
- 8
- Pages
- 855-862
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2885684012
- Cited by
- 305
- References
- 24
- FWCI
- 20.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. https://app.cochat.ai/papers/10.1093/jnci/djy106
- The paper
- Shimelis, H., LaDuca, H., Hu, C., Hart, S. N., Na, J., Thomas, A., Akinhanmi, M., Moore, R. M., Brauch, H., Cox, A., Eccles, D. M., Ewart-Toland, A., Fasching, P. A., Fostira, F., Garber, J., Godwin, A. K., Konstantopoulou, I., Nevanlinna, H., Sharma, P., . . . Couch, F. J. (2018). Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.